Pulmonary arterial hypertension (PAH) is a rare and life-threatening disorder marked by considerable morbidity and mortality. Despite the availability of a wide array of drugs for PAH management, high unmet need remains for drugs that offer improved survival, long-term efficacy, and better QOL. According to physicians interviewed by DRG, there is scope for novel therapies offering patients a better prognosis. Based on quantified physician perception of current therapies, we discuss the attractiveness of drug attributes and the implications for PAH drug development. Understanding the influence of key efficacy, safety/tolerability, and nonclinical attributes on physician prescribing behavior is important to achieve commercial success in this competitive landscape. Our conjoint analysis reveals the key trade-offs that surveyed physicians are willing to make for these attributes when considering new treatment options for PAH.
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 61 U.S. and 32 European cardiologists and pulmonologists fielded in July 2018.
Key companies: Actelion, Bayer, Gilead, GlaxoSmithkline, Pfizer, and United Therapeutics.
Key drugs: Adempas, Uptravi, Letairis, Opsumit, Adcirca, Orenitram, and sildenafil.